News AstraZeneca’s volrustomig hits Phase 3 setback in lung cance... In another blow to its late-stage pipeline, AstraZeneca has pulled the plug on a phase 3 trial of its lung cancer treatment volrustomig.
News Sandoz adds 10 biosimilars through $322m Henlius deal Sandoz is set to add up to 10 new biosimilar assets to its portfolio under a new collaboration deal with China’s Shanghai Henlius Biotech.
News Australia first for Hansa’s Idefirix in commercial kidney tr... Hansa has announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix.
News After failure in sickle cell, Fulcrum merges with Slate Following the failure of its sickle cell programme, Fulcrum Therapeutics will merge with Slate Medicines to advance Slate's migraine therapy.
News Sanofi to lay off 229 Blueprint employees, close offices A year after its $9.1bn acquisition of Blueprint Medicines, Sanofi is moving out of Blueprint's Cambridge, MA offices and letting 229 employees go.
News Capricor’s DMD hope still strong, as it shares financials Capricor shares second quarter financials as FDA reconsiders BLA for DMD therapy deramiocel.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.